Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Initiative Capital Romandie

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 9
Average round size
info
The average size of a deal this fund participated in
$10M
Portfolio companies 5
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.44
Exits 1
Key employees Soon

Areas of investment

  • Health Care
  • Medical Device
  • Biotechnology
  • Neuroscience
  • Health Diagnostics
Summary

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Viroblock, Diagnoplex, Endosense. Among the most successful fund investment fields, there are Personal Health, Medical Device. The fund has exact preference in some founders of portfolio startups.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Initiative Capital Romandie, startups are often financed by Neomed Management, Ysios Capital, VI Partners AG. The meaningful sponsors for the fund in investment in the same round are BioMedPartners, BB Biotech Ventures, Neomed Management. In the next rounds fund is usually obtained by BioMedPartners, Banexi Ventures, BB Biotech Ventures.

The fund is constantly included in less than 2 deals per year. Opposing the other organizations, this Initiative Capital Romandie works on 15 percentage points less the average amount of lead investments. The important activity for fund was in 2013. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2013.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Initiative Capital Romandie:
Typical Co-investors
Initiative Capital Romandie is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Initiative Capital Romandie:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AsiaPay -
Binghong Chuangye China, Henan, Zhengzhou
Edap 2007 Barcelona, Catalonia, Spain
Energia Ventures Canada, Fredericton, New Brunswick
ESB International County Dublin, Dublin, Ireland
Explorer Equity Group Florida, North Palm Beach, United States
Fresh Your Life Beijing, Beijing, China
Gate.io Illinois, Malta, United States
Grosvenor Venture Partners England, London, United Kingdom
Impact Angel Fund -
Market Tech Holdings Castel, Guernsey, Guernsey
Nantong Lanwan Chuangtou China, Haimen, Jiangsu
Neuromuscular Research Association Basel Basel, Basel-Stadt, Switzerland
OPALIC France, Ile-de-France, Versailles
Private Angel Syndicate -
Prototron Estonia, Harjumaa, Tallinn
Qianhe Capital Beijing, Beijing, China
Tesi Finland, Helsinki, Southern Finland
Yantai Yuanjin Investment China, Jinan, Shandong

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

PicoDRILL

Nanotechnology
$6M01 Aug 2017 Lausanne, Vaud, Switzerland

Aleva Neurotherapeutics

Health Care
Health Diagnostics
Medical Device
Neuroscience
$18M27 May 2016 Lausanne, Vaud, Switzerland

Endosense

Biotechnology
Health Care
Medical Device
Surgical Devices
Therapeutics
$40M27 Nov 2013 Geneva, Geneva, Switzerland

Aleva Neurotherapeutics

Health Care
Health Diagnostics
Medical Device
Neuroscience
$4M10 Apr 2012 Lausanne, Vaud, Switzerland

Aleva Neurotherapeutics

Health Care
Health Diagnostics
Medical Device
Neuroscience
$11M25 Aug 2011 Lausanne, Vaud, Switzerland

Viroblock

Biotechnology
Fitness
Health Care
Medical
Personal Health
05 Feb 2010 Geneva, Switzerland

Viroblock

Biotechnology
Fitness
Health Care
Medical
Personal Health
20 Jul 2007 Geneva, Switzerland

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Initiative Capital Romandie?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 9
Average round size 10M
Peak activity year 2013
Lead investments 0
Follow on index 0.44
Exits 1
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

PicoDRILL

Nanotechnology
$6M01 Aug 2017 Lausanne, Vaud, Switzerland

Aleva Neurotherapeutics

Health Care
Health Diagnostics
Medical Device
Neuroscience
$18M27 May 2016 Lausanne, Vaud, Switzerland

Endosense

Biotechnology
Health Care
Medical Device
Surgical Devices
Therapeutics
$40M27 Nov 2013 Geneva, Geneva, Switzerland

Aleva Neurotherapeutics

Health Care
Health Diagnostics
Medical Device
Neuroscience
$4M10 Apr 2012 Lausanne, Vaud, Switzerland

Aleva Neurotherapeutics

Health Care
Health Diagnostics
Medical Device
Neuroscience
$11M25 Aug 2011 Lausanne, Vaud, Switzerland

Viroblock

Biotechnology
Fitness
Health Care
Medical
Personal Health
05 Feb 2010 Geneva, Switzerland

Viroblock

Biotechnology
Fitness
Health Care
Medical
Personal Health
20 Jul 2007 Geneva, Switzerland
Crunchbase icon

Content report

The following text will be sent to our editors: